RxDoctor Payments Data

Raffaella Umeton, MD

Neurology · Burlington, MANPI 1801273859

Payments from drug & device makers

$224,764in general payments, 2019–2025

Across 11 payments — averaging $20,433 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$219K
  • Lilly USA, LLC$6K
  • Sanofi$96
  • Biogen$54

What the payments were for

  • Consulting fees$4,30072%
  • Travel & lodging$1,49925%
  • Food & beverage$962%
  • Education$561%

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis3$218,813
Lilly USA, LLC6$5,801
Sanofi1$96
Biogen1$54

How this compares

$224,764 in reported general payments places this provider in the 85th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$13,349
Medicare patients
89
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab19$175,437
TecfideraDimethyl Fumarate11$93,638
CopaxoneGlatiramer Acetate13$84,011
UbrelvyUbrogepant42$54,915
QuliptaAtogepant27$39,664
Emgality PenGalcanezumab-Gnlm50$39,438
Glatiramer Acetate18$36,791
Nurtec OdtRimegepant Sulfate27$31,274
Ajovy AutoinjectorFremanezumab-Vfrm11$21,806
Aimovig AutoinjectorErenumab-Aooe20$20,625
Teriflunomide13$8,278
Dalfampridine ErDalfampridine21$2,237
Topiramate35$808
Gabapentin75$781
Divalproex Sodium15$501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$54$93,63811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 761 neurology providers in Massachusetts.

Other neurology in Burlington

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →